Nutritional Vitamin B6 Deficiency Impairs Lipid Me Tabolism and Leads

Total Page:16

File Type:pdf, Size:1020Kb

Nutritional Vitamin B6 Deficiency Impairs Lipid Me Tabolism and Leads J Nutr Sci Vitaminol, 47, 306-310, 2001 Xanthurenic Acid Inhibits Metal Ion-Induced Lipid Peroxidation and Protects NADP-Isocitrate Dehydrogenase from Oxidative Inactivation Keiko MURAKAMI,Masae ITO and Masataka YOSHINO* Department of Biochemistry, Aichi Medical University School of Medicine,Nagakute, Aichi 480-1195, Japan (ReceivedJanuary 26, 2001) Summary Vitamin B6 deficiency increases the lipid peroxidation and the synthesis of xanthurenic acid from tryptophan. Antioxidant properties of xanthurenic acid were exam ined in relation to the coordination of transition metals. Xanthurenic acid inhibited the for mation of thiobarbituric acid-reactive substances as a marker of iron-mediated lipid peroxi dation and copper-dependent oxidation of low density lipoprotein. NADP-isocitrate dehydro genase (EC 1.1.1.42), a principal NADPH-generating enzyme for the antioxidant defense system, was inactivated by reduced iron and copper, and xanthurenic acid protected the en zyme from the Fe2+-mediated inactivation. Xanthurenic acid may participate in the en hanced regeneration of reduced glutathione by stimulating the NADPH supply. Xanthurenic acid further enhanced the autooxidation of Fe2+ ion. Other tryptophan metabolites such as kynurenic acid and various quinoline compounds did not inhibit the lipid peroxidation and the inactivation of NADP-isocitrate dehydrogenase, and they showed little or no effect on the Fe2+ autooxidation. The antioxidant properties of xanthurenic acid are related to the metal-chelating activity and probably to the enhanced oxidation of reduced transition met als as a prooxidant, and this action may be due to the electron deficient nature of this com pound. Key Words xanthurenic acid, antioxidant, LDL, NADP-isocitrate dehydrogenase, reactive oxygen species Nutritional vitamin B6 deficiency impairs lipid me Lipid peroxidation. Lipid peroxidation was deter tabolism and leads to lipid peroxidation by a decrease in mined as the formation of thiobarbituric acid-reactive some antioxidant factors such as vitamin E and reduced substances (7) by iron/ascorbate system with liver mi glutathione (1, 2). Vitamin B6 deficiency further causes crosomes (8). The reaction mixture of 1mL contained an increased excretion of xanthurenic acid, and the in 60mM Tris-HCl buffer (pH 7.5), 10ƒÊM FeCl3, 0.5mM creased xanthurenic acid level is an indicator of vitamin ascorbic acid, and 0.2mg microsomal fraction in the B6 deficiency (3). Many reports suggest that xan presence and absence of xanthurenic acid or kynurenic thurenic acid is closely related to the pathogenesis of acid. Lipid peroxides produced were determined after in several diseases (4-6), although the physiological role cubation for 10min (7). of this compound is unknown. In this paper we show Autooxidation of Fe2+ ion. The interaction of xan that xanthurenic acid acts as an antioxidant by inhibit thurenic acid and quinoline compounds with iron was ing lipid peroxidation and copper-dependent oxidation evaluated by the effect of these compounds on the rate of low-density lipoprotein. Xanthurenic acid also pro of autooxidation of Fe2+ ion, as described previously (8). tected NADP-isocitrate dehydrogenase (EC 1.1.1.42), The samples of 1mL contained 10mM Tris-HCl (pH the reduced NADP generating enzyme, from the iron 7. 1), 0.1mM FeSO4, and the additive. The reaction was and copper-mediated inactivation. The antioxidant ac started by the addition of FeSO4. Aliquots of 0.2mL tion of xanthurenic acid may counteract the peroxida were mixed with 0.1mL of 1mM bathophenanthroline tive damage because of vitamin B6 deficiency. disulfonate at appropriate intervals, and the absorbance at 540nm was measured. MATERIALS AND METHODS Inactivation of NADP isocitrate dehydrogenase. Materials. NADP isocitrate dehydrogenase was a Purified NADP isocitrate dehydrogenase of 1.5ƒÊg was product of Oriental Yeast Co. (Osaka, Japan). inactivated by preincubating for 2.5min with various Xanthurenic acid, kynurenic acid, anthranilic acid, concentrations of FeCl2 in 1mL of 40mM Tris-HCl quinolinic acid derivatives, human low-density lipopro buffer (pH 7.1) containing 0.25mM threo-Ds-isocitrate, tein (LDL), bathophenanthroline disulfonate, threo-Ds the substrate, and 2.5mM MgCl2 in the absence and isocitrate, and NADP were products of Sigma-Aldrich presence of various concentrations of xanthurenic acid -Japan (Tokyo, Japan). and its related compounds. Enzyme reaction was started by the addition of 0.25mM NADP to the mix * To whom correspondence should be addressed . ture, and changes in absorbance at 340nm were fol E-mail: [email protected] lowed (9). 306 Xanthurenic Acid as Antioxidant 307 Oxidation of human low-density lipoprotein. The oxi dependent LDL oxidation by prolonging lag phase and dation of LDL was determined as described previously by slightly suppressing propagation rate. 8-Hydroxy (10). LDL was diluted to the concentration of 60ƒÊg/mL quinoline caused a complete inhibition of LDL oxida with 10mM potassium phosphate buffer (pH 7.4) con tion, but quinaldic acid showed no effect on the oxida taining 1.5ƒÊM EDTA and 0.15M NaCl. LDL oxidation tion (Fig. 2, 3). was performed at 37•Ž in 1mL of the phosphate buffer NADP-isocitrate dehydrogenase, the principal (pH 7.4) containing 2ƒÊM CuSO4, 5ƒÊM xanthurenic NADPH generating enzyme, was irreversibly inacti acid or quinoline compounds, and 0.15M NaCl. The vated by Fe2+ ion, and the concentration of ferrous ion progress of oxidation was monitored spectrophotomet required for the enzyme inactivation was about 3 to rically (Shimadzu 1600, Tokyo, Japan, equipped with a 4ƒÊM (Fig. 4). Fe3+ ion did not inactivate the enzyme Peltier-thermostatted six-cell holder) by the formation (data not shown). The addition of xanthurenic acid of conjugated dienes at 234nm (10). completely protected the enzyme from the ferrous Spectrophotometric analysis of the interaction of xan ion-dependent inactivation. 8-Hydroxyquinoline also thurenic acid with iron. Stock solutions of xanthurenic acid were diluted to 20 or 25ƒÊM solutions in 10mM Tris-HCl buffer (pH 7.4). Absorption spectra were recorded from 300 to 600nm. Scans were started by the addition of 0.1mM FeSO4 and repeated at intervals of 1 min. The spectra of FeCl3 and FeSO4 solution were also recorded. RESULTS We examined the effect of xanthurenic acid and kynurenic acid as principal tryptophan metabolites on the microsomal lipid peroxidation. The incubation of microsomes with iron and ascorbate produced thiobar bituric acid-reactive substances as a marker of lipid per oxidation. The antioxidant effect was determined as the inhibition of the formation of the thiobarbituric acid-re Fig. 2. Effect of xanthurenic acid and its related com active substances by quinoline compounds. The con pounds on the copper-dependent oxidation of low density lipoprotein. LDL was diluted to a concentra centrations of xanthurenic acid required for 50% inhi tion of 60ƒÊg/mL, with 10mM potassium phosphate bition of the peroxidation were about 30ƒÊM, but buffer (pH 7.4) containing 1.5ƒÊM EDTA and 0.15M kynurenic acid showed no inhibitory effect (Fig. 1). NaCl, and LDL oxidation was started at 37•Ž by the The addition of 2ƒÊM copper caused the oxidation of addition of 2ƒÊM CuSO4 in the absence and presence of LDL with the concomitant formation of conjugated 5ƒÊM xanthurenic acid or quinoline compounds. The dienes (Fig. 2). Xanthurenic acid inhibited copper progress of oxidation was monitored spectrophoto metrically by means of a thermostatic control (37•Ž) and an automatically exchangeable six-position cu vette holder operating at 234nm (10). Curve 1, no addition; curve 2, xanthurenic acid added; curve 3, quinaldic acid added; curve 4, 8-hydroxyquinoline added. Fig. 1. Effect of xanthurenic acid and kynurenic acid on the iron-mediated lipid peroxidation of rat liver microsomes. Lipid peroxidation was induced by 10ƒÊM FeCl3, 0.5mM ascorbic acid, and 0.2mg microsomal fraction (8) in the presence and absence of xan thurenic acid or kynurenic acid. The mixture was in cubated at 37•Ž for 10min, and the reaction was stopped by the addition of 100% trichloroacetic acid. Lipid peroxides produced were expressed as the thio barbituric acid-reactive substances (7). •œ, xan thurenic acid; •¢, kynurenic acid. Fig. 3. Structure of quinoline compounds. 308 MURAKAMI K et al. showed a complete protection of the enzyme, but compound required for the 50% protection of the kynurenic acid and quinaldic acid showed no protective enzyme was 80 to 90ƒÊM (Fig. 5). The inactivation by effect on the enzyme (Fig. 4). We further examined the reduced copper of NADP-isocitrate dehydrogenase was effect of the increasing concentration of xanthurenic also protected by xanthurenic acid (Fig. 5). acid on the iron-mediated inactivation of NADP-iso The effect of xanthurenic acid and its related citrate dehydrogenase, and the concentration of the compounds on the rate of Fe2+ autooxidation was examined. After incubation of FeSO4 with quinoline compounds or tryptophan metabolites, Fe2+ ion was determined by bathophenanthroline disulfonate. Xanthurenic acid increased the rate of Fe2+ oxidation markedly, and 8-hydroxyquinoline showed a large stim Fig. 4. Inactivation of NADP-isocitrate dehydrogenase by Fe2+ ion in the presence of xanthurenic acid and its related compounds. NADP-isocitrate dehydrogenase was incubated for 2.5min with a mixture containing various concentrations of FeCl2, 0.25mM threo-Ds isocitrate, 2.5mM MgCl2, and 40mM Tris-HCl buffer Fig. 5. Effect of increasing concentrations of xan thurenic acid on the Feet and Cut-mediated inactiva (pH 7.1) in the absence and presence of xanthurenic acid and its related compounds. Activity was deter tion of NADP-isocitrate dehydrogenase. The enzyme mined by the addition of 0.25mM NADP. •ž, no addi was inactivated by iron or copper of 10ƒÊM, and the tion; • , 0.1mM xanthurenic acid added; •›, 0.1mM 8 conditions were similar to those in the legend to Fig. 4. •Ÿ hydroxyquinoline added; •~, 0.1mM quinaldic acid , Inactivation by 10ƒÊM FeC12; •¢, Inactivation by added; •£, 0.1mM kynurenic acid added. 10ƒÊM CuSO4 plus 0.5mM ascorbate.
Recommended publications
  • Altered Expression and Function of Mitochondrial Я-Oxidation Enzymes
    0031-3998/01/5001-0083 PEDIATRIC RESEARCH Vol. 50, No. 1, 2001 Copyright © 2001 International Pediatric Research Foundation, Inc. Printed in U.S.A. Altered Expression and Function of Mitochondrial ␤-Oxidation Enzymes in Juvenile Intrauterine-Growth-Retarded Rat Skeletal Muscle ROBERT H. LANE, DAVID E. KELLEY, VLADIMIR H. RITOV, ANNA E. TSIRKA, AND ELISA M. GRUETZMACHER Department of Pediatrics, UCLA School of Medicine, Mattel Children’s Hospital at UCLA, Los Angeles, California 90095, U.S.A. [R.H.L.]; and Departments of Internal Medicine [D.E.K., V.H.R.] and Pediatrics [R.H.L., A.E.T., E.M.G.], University of Pittsburgh School of Medicine, Magee-Womens Research Institute, Pittsburgh, Pennsylvania 15213, U.S.A. ABSTRACT Uteroplacental insufficiency and subsequent intrauterine creased in IUGR skeletal muscle mitochondria, and isocitrate growth retardation (IUGR) affects postnatal metabolism. In ju- dehydrogenase activity was unchanged. Interestingly, skeletal venile rats, IUGR alters skeletal muscle mitochondrial gene muscle triglycerides were significantly increased in IUGR skel- expression and reduces mitochondrial NADϩ/NADH ratios, both etal muscle. We conclude that uteroplacental insufficiency alters of which affect ␤-oxidation flux. We therefore hypothesized that IUGR skeletal muscle mitochondrial lipid metabolism, and we gene expression and function of mitochondrial ␤-oxidation en- speculate that the changes observed in this study play a role in zymes would be altered in juvenile IUGR skeletal muscle. To test the long-term morbidity associated with IUGR. (Pediatr Res 50: this hypothesis, mRNA levels of five key mitochondrial enzymes 83–90, 2001) (carnitine palmitoyltransferase I, trifunctional protein of ␤-oxi- dation, uncoupling protein-3, isocitrate dehydrogenase, and mi- Abbreviations tochondrial malate dehydrogenase) and intramuscular triglycer- CPTI, carnitine palmitoyltransferase I ides were quantified in 21-d-old (preweaning) IUGR and control IUGR, intrauterine growth retardation rat skeletal muscle.
    [Show full text]
  • Isocitrate Dehydrogenase Activity Assay Kit (MAK062)
    Isocitrate Dehydrogenase Activity Assay Kit Catalog Number MAK062 Storage Temperature –20 C TECHNICAL BULLETIN Product Description Developer 1 vl Isocitrate dehydrogenase (IDH) catalyzes the Catalog Number MAK062E conversion of isocitrate to -ketoglutarate. In eukaryotes, there are three isozymes of IDH, the IDH Positive Control (NADP+) 20 L mitochondrial IDH2 and IDH3, and the cytoplasmic/ Catalog Number MAK062F peroxisomal IDH1. All three IDH family members require the presence of a divalent cation (Mg2+ or Mn2+) NADH Standard, 0.5 mole 1 vl and either the electron-accepting cofactor NADP+ (IDH1 Catalog Number MAK062G and IDH2) or NAD+ (IDH3) for their enzymatic activity. IDH1 and IDH2 mutations resulting in neomorphic Reagents and Equipment Required but Not enzymatic activity are found in certain cancers such as Provided. glioblastoma, acute myeloid leukemia, and colon 96 well flat-bottom plate – It is recommended to use cancer. This neoactivity shows a change in the clear plates for colorimetric assays. substrate specificity resulting in the conversion of Spectrophotometric multiwell plate reader -ketoglutarate to 2-hydroxyglutarate. Mutations in IDH family members are also associated with Ollier disease Precautions and Disclaimer and Maffucci syndrome. This product is for R&D use only, not for drug, household, or other uses. Please consult the Material The Isocitrate Dehydrogenase Activity Assay kit Safety Data Sheet for information regarding hazards provides a simple and direct procedure for measuring and safe handling practices. + + + NADP -dependent, NAD -dependent, or both NADP + and NAD -dependent IDH activity in a variety of Preparation Instructions samples. IDH activity is determined using isocitrate as Briefly centrifuge vials before opening.
    [Show full text]
  • Isocitrate Dehydrogenase 1 (NADP+) (I5036)
    Isocitrate Dehydrogenase 1 (NADP+), human recombinant, expressed in Escherichia coli Catalog Number I5036 Storage Temperature –20 °C CAS RN 9028-48-2 IDH1 and IDH2 have frequent genetic alterations in EC 1.1.1.42 acute myeloid leukemia4 and better understanding of Systematic name: Isocitrate:NADP+ oxidoreductase these mutations may lead to an improvement of (decarboxylating) individual cancer risk assessment.6 In addition other studies have shown loss of IDH1 in bladder cancer Synonyms: IDH1, cytosolic NADP(+)-dependent patients during tumor development suggesting this may isocitrate dehydrogenase, isocitrate:NADP+ be involved in tumor progression and metastasis.7 oxidoreductase (decarboxylating), Isocitric Dehydrogenase, ICD1, PICD, IDPC, ICDC, This product is lyophilized from a solution containing oxalosuccinate decarboxylase Tris-HCl, pH 8.0, with trehalose, ammonium sulfate, and DTT. Product Description Isocitrate dehydrogenase (NADP+) [EC 1.1.1.42] is a Purity: ³90% (SDS-PAGE) Krebs cycle enzyme, which converts isocitrate to a-ketoglutarate. The flow of isocitrate through the Specific activity: ³80 units/mg protein glyoxylate bypass is regulated by phosphorylation of isocitrate dehydrogenase, which competes for a Unit definition: 1 unit corresponds to the amount of 1 common substrate (isocitrate) with isocitrate lyase. enzyme, which converts 1 mmole of DL-isocitrate to The activity of the enzyme is dependent on the a-ketoglutarate per minute at pH 7.4 and 37 °C (NADP formation of a magnesium or manganese-isocitrate as cofactor). The activity is measured by observing the 2 complex. reduction of NADP to NADPH at 340 nm in the 7 presence of 4 mM DL-isocitrate and 2 mM MnSO4.
    [Show full text]
  • Aldehyde Dehydrogenase 2 Activation and Coevolution of Its Εpkc
    Nene et al. Journal of Biomedical Science (2017) 24:3 DOI 10.1186/s12929-016-0312-x RESEARCH Open Access Aldehyde dehydrogenase 2 activation and coevolution of its εPKC-mediated phosphorylation sites Aishwarya Nene†, Che-Hong Chen*† , Marie-Hélène Disatnik, Leslie Cruz and Daria Mochly-Rosen Abstract Background: Mitochondrial aldehyde dehydrogenase 2 (ALDH2) is a key enzyme for the metabolism of many toxic aldehydes such as acetaldehyde, derived from alcohol drinking, and 4HNE, an oxidative stress-derived lipid peroxidation aldehyde. Post-translational enhancement of ALDH2 activity can be achieved by serine/threonine phosphorylation by epsilon protein kinase C (εPKC). Elevated ALDH2 is beneficial in reducing injury following myocardial infarction, stroke and other oxidative stress and aldehyde toxicity-related diseases. We have previously identified three εPKC phosphorylation sites, threonine 185 (T185), serine 279 (S279) and threonine 412 (T412), on ALDH2. Here we further characterized the role and contribution of each phosphorylation site to the enhancement of enzymatic activity by εPKC. Methods: Each individual phosphorylation site was mutated to a negatively charged amino acid, glutamate, to mimic a phosphorylation, or to a non-phosphorylatable amino acid, alanine. ALDH2 enzyme activities and protection against 4HNE inactivation were measured in the presence or absence of εPKC phosphorylation in vitro. Coevolution of ALDH2 and its εPKC phosphorylation sites was delineated by multiple sequence alignments among a diverse range of species and within the ALDH multigene family. Results: We identified S279 as a critical εPKC phosphorylation site in the activation of ALDH2. The critical catalytic site, cysteine 302 (C302) of ALDH2 is susceptible to adduct formation by reactive aldehyde, 4HNE, which readily renders the enzyme inactive.
    [Show full text]
  • Citric Acid Cycle
    CHEM464 / Medh, J.D. The Citric Acid Cycle Citric Acid Cycle: Central Role in Catabolism • Stage II of catabolism involves the conversion of carbohydrates, fats and aminoacids into acetylCoA • In aerobic organisms, citric acid cycle makes up the final stage of catabolism when acetyl CoA is completely oxidized to CO2. • Also called Krebs cycle or tricarboxylic acid (TCA) cycle. • It is a central integrative pathway that harvests chemical energy from biological fuel in the form of electrons in NADH and FADH2 (oxidation is loss of electrons). • NADH and FADH2 transfer electrons via the electron transport chain to final electron acceptor, O2, to form H2O. Entry of Pyruvate into the TCA cycle • Pyruvate is formed in the cytosol as a product of glycolysis • For entry into the TCA cycle, it has to be converted to Acetyl CoA. • Oxidation of pyruvate to acetyl CoA is catalyzed by the pyruvate dehydrogenase complex in the mitochondria • Mitochondria consist of inner and outer membranes and the matrix • Enzymes of the PDH complex and the TCA cycle (except succinate dehydrogenase) are in the matrix • Pyruvate translocase is an antiporter present in the inner mitochondrial membrane that allows entry of a molecule of pyruvate in exchange for a hydroxide ion. 1 CHEM464 / Medh, J.D. The Citric Acid Cycle The Pyruvate Dehydrogenase (PDH) complex • The PDH complex consists of 3 enzymes. They are: pyruvate dehydrogenase (E1), Dihydrolipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E3). • It has 5 cofactors: CoASH, NAD+, lipoamide, TPP and FAD. CoASH and NAD+ participate stoichiometrically in the reaction, the other 3 cofactors have catalytic functions.
    [Show full text]
  • Biological Application and Disease of Oxidoreductase Enzymes Mezgebu Legesse Habte and Etsegenet Assefa Beyene
    Chapter Biological Application and Disease of Oxidoreductase Enzymes Mezgebu Legesse Habte and Etsegenet Assefa Beyene Abstract In biochemistry, oxidoreductase is a large group of enzymes that are involved in redox reaction in living organisms and in the laboratory. Oxidoreductase enzymes catalyze reaction involving oxygen insertion, hydride transfer, proton extraction, and other essential steps. There are a number of metabolic pathways like glycolysis, Krebs cycle, electron transport chain and oxidative phosphorylation, drug transfor- mation and detoxification in liver, photosynthesis in chloroplast of plants, etc. that require the direct involvements of oxidoreductase enzymes. In addition, degrada- tion of old and unnecessary endogenous biomolecules is catalyzed by a family of oxidoreductase enzymes, e.g., xanthine oxidoreductase. Oxidoreductase enzymes use NAD, FAD, or NADP as a cofactor and their efficiency, specificity, good biode- gradability, and being studied well make it fit well for industrial applications. In the near future, oxidoreductase may be utilized as the best biocatalyst in pharmaceuti- cal, food processing, and other industries. Oxidoreductase play a significant role in the field of disease diagnosis, prognosis, and treatment. By analyzing the activities of enzymes and changes of certain substances in the body fluids, the number of disease conditions can be diagnosed. Disorders resulting from deficiency (quantita- tive and qualitative) and excess of oxidoreductase, which may contribute to the metabolic abnormalities and decreased normal performance of life, are becoming common. Keywords: biocatalyst, biological application, disease, metabolism, mutation, oxidoreductase 1. Introduction Oxidoreductases, which includes oxidase, oxygenase, peroxidase, dehydroge- nase, and others, are enzymes that catalyze redox reaction in living organisms and in the laboratory [1].
    [Show full text]
  • Control of the Antitumor Immune Response by Cancer Metabolism
    cells Review Control of the Antitumor Immune Response by Cancer Metabolism Charlotte Domblides 1,2 , Lydia Lartigue 3,† and Benjamin Faustin 1,4,*,† 1 Bordeaux University, CNRS, UMR 5164, ImmunoConcEpT, 33000 Bordeaux, France; [email protected] 2 Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital-CHU, 33000 Bordeaux, France 3 Curematch, Inc., 6440 Lusk Bvld, San Diego, CA 92121, USA; [email protected] 4 Cellomet, CGFB, 146 Rue léo Saignat, F-33000 Bordeaux, France * Correspondence: [email protected]; Tel.: +33-(0)557-571-470 † These authors contributed equally to this work. Received: 22 December 2018; Accepted: 28 January 2019; Published: 31 January 2019 Abstract: The metabolic reprogramming of tumor cells and immune escape are two major hallmarks of cancer cells. The metabolic changes that occur during tumorigenesis, enabling survival and proliferation, are described for both solid and hematological malignancies. Concurrently, tumor cells have deployed mechanisms to escape immune cell recognition and destruction. Additionally, therapeutic blocking of tumor-mediated immunosuppression has proven to have an unprecedented positive impact in clinical oncology. Increased evidence suggests that cancer metabolism not only plays a crucial role in cancer signaling for sustaining tumorigenesis and survival, but also has wider implications in the regulation of antitumor immune signaling through both the release of signaling molecules and the expression of immune membrane ligands. Here, we review these molecular events to highlight the contribution of cancer cell metabolic reprogramming on the shaping of the antitumor immune response. Keywords: cancer; metabolism; immunity 1. Introduction Both the innate and adaptive immune systems have now established roles in the host defense against cancers through various mechanisms, which are raising an unprecedented development of modern cancer immunotherapies.
    [Show full text]
  • (IDH1) Helps Regulate Catalysis and Ph Sensitivity
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.19.049387; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Mechanisms of pH-dependent IDH1 catalysis An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity Lucas A. Luna1, Zachary Lesecq1, Katharine A. White2, An Hoang1, David A. Scott3, Olga Zagnitko3, Andrey A. Bobkov3, Diane L. Barber4, Jamie M. Schiffer5, Daniel G. Isom6, and Christal D. Sohl1,‡,§ From the 1Department of Chemistry and Biochemistry, San Diego State University, San Diego, CA, 92182; 2Harper Cancer Research Institute, Department of Chemistry and Biochemistry, University of Notre Dame, South Bend, IN, 46617; 3Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037; 4Department of Cell and Tissue Biology, University of California, San Francisco, CA, 94143; 5Janssen Research and Development, 3210 Merryfield Row, San Diego, CA, 92121; 6Department of Pharmacology, Sylvester Comprehensive Cancer Center, and Center for Computational Sciences, University of Miami, Miami, FL, 33136 Running title: Mechanisms of pH-dependent IDH1 catalysis ‡To whom correspondence should be addressed: Christal D. Sohl, Department of Chemistry and Biochemistry, San Diego State University, CSL 328, 5500 Campanile Dr., San Diego, California 92182, Email: [email protected]; Telephone: (619) 594-2053. §This paper is dedicated to the memory of our dear colleague and friend, Michelle Evon Scott (1990-2020). Keywords: enzyme kinetics, cancer, tumor metabolism, pH regulation, post-translational modification (PTM), buried ionizable residues ABSTRACT protonation states leading to conformational Isocitrate dehydrogenase 1 (IDH1) changes that regulate catalysis.
    [Show full text]
  • Mitochondrial Aldehyde Dehydrogenase (ALDH2) Protects
    Zhang et al. BMC Medicine 2012, 10:40 http://www.biomedcentral.com/1741-7015/10/40 RESEARCHARTICLE Open Access Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3b and mitochondrial function Yingmei Zhang1,2, Sara A Babcock2, Nan Hu2, Jacalyn R Maris2, Haichang Wang1 and Jun Ren1,2* Abstract Background: Mitochondrial aldehyde dehydrogenase (ALDH2) displays some promise in the protection against cardiovascular diseases although its role in diabetes has not been elucidated. Methods: This study was designed to evaluate the impact of ALDH2 on streptozotocin-induced diabetic cardiomyopathy. Friendly virus B(FVB) and ALDH2 transgenic mice were treated with streptozotocin (intraperitoneal injection of 200 mg/kg) to induce diabetes. Results: Echocardiographic evaluation revealed reduced fractional shortening, increased end-systolic and -diastolic diameter, and decreased wall thickness in streptozotocin-treated FVB mice. Streptozotocin led to a reduced respiratory exchange ratio; myocardial apoptosis and mitochondrial damage; cardiomyocyte contractile and intracellular Ca2+ defects, including depressed peak shortening and maximal velocity of shortening and relengthening; prolonged duration of shortening and relengthening; and dampened intracellular Ca2+ rise and clearance. Western blot analysis revealed disrupted phosphorylation of Akt, glycogen synthase kinase-3b and Foxo3a (but not mammalian target of rapamycin), elevated PTEN phosphorylation and downregulated expression of mitochondrial proteins, peroxisome proliferator-activated receptor g coactivator 1a and UCP-2. Intriguingly, ALDH2 attenuated or ablated streptozotocin- induced echocardiographic, mitochondrial, apoptotic and myocardial contractile and intracellular Ca2+ anomalies as well as changes in the phosphorylation of Akt, glycogen synthase kinase-3b, Foxo3a and phosphatase and tensin homologue on chromosome ten, despite persistent hyperglycemia and a low respiratory exchange ratio.
    [Show full text]
  • Isocitrate Dehydrogenase Status and Molecular Subclasses of Glioma and Glioblastoma
    Neurosurg Focus 37 (6):E13, 2014 ©AANS, 2014 Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma SAMEER AGNIHOTRI, PH.D.,1 KENNETH D. ALDAPE, M.D.,3 AND GELAREH ZADEH, M.D., PH.D.1,2 1Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children; 2Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Ontario, Canada; and 3Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Diffuse gliomas and secondary glioblastomas (GBMs) that develop from low-grade gliomas are a common and incurable class of brain tumor. Mutations in the metabolic enzyme glioblastomas (IDH1) represent a distinguish- ing feature of low-grade gliomas and secondary GBMs. IDH1 mutations are one of the most common and earli- est detectable genetic alterations in low-grade diffuse gliomas, and evidence supports this mutation as a driver of gliomagenesis. Here, the authors highlight the biological consequences of IDH1 mutations in gliomas, the clinical and therapeutic/diagnostic implications, and the molecular subtypes of these tumors. They also explore, in brief, the non-IDH1–mutated gliomas, including primary GBMs, and the molecular subtypes and drivers of these tumors. A fundamental understanding of the diversity of GBMs and lower-grade gliomas will ultimately allow for more effec- tive treatments and predictors of survival. (http://thejns.org/doi/abs/10.3171/2014.9.FOCUS14505) KEY WORDS • glioblastoma • IDH1 • tumor metabolism LIOBLASTOMA (GBM) is the most common brain in gliomas, the clinical and therapeutic/diagnostic impli- tumor type, and despite surgery, radiation, and cations, and the molecular subclasses of non-IDH1–mu- chemotherapy, it is incurable.27,64 The major- tated gliomas.
    [Show full text]
  • Mitochondrial Protein Interaction Landscape of SS-31
    Mitochondrial protein interaction landscape of SS-31 Juan D. Chaveza, Xiaoting Tanga, Matthew D. Campbellb, Gustavo Reyesb, Philip A. Kramerb, Rudy Stuppardb, Andrew Kellera, Huiliang Zhangc, Peter S. Rabinovitchc, David J. Marcinekb, and James E. Brucea,1 aDepartment of Genome Sciences, University of Washington, Seattle, WA 98105; bDepartment of Radiology, University of Washington, Seattle, WA 98105; and cDepartment of Pathology, University of Washington, Seattle, WA 98195 Edited by Carol Robinson, University of Oxford, Oxford, United Kingdom, and approved May 8, 2020 (received for review February 6, 2020) Mitochondrial dysfunction underlies the etiology of a broad enzymatic activities and stabilities of both individual protein spectrum of diseases including heart disease, cancer, neurodegen- subunits and protein supercomplexes involved in mitochondrial erative diseases, and the general aging process. Therapeutics that respiration. For example, CL plays an essential role in the olig- restore healthy mitochondrial function hold promise for treatment omerization of the c-rings and lubrication of its rotation in ATP of these conditions. The synthetic tetrapeptide, elamipretide (SS- synthase (CV), which can influence the stability of cristae 31), improves mitochondrial function, but mechanistic details of its structure through dimerization (9, 10); CL acts as glue holding pharmacological effects are unknown. Reportedly, SS-31 primarily respiratory supercomplexes (CIII and CIV) together and steer- interacts with the phospholipid cardiolipin in the inner mitochon- ing their assembly and organization (11, 12); and the binding drial membrane. Here we utilize chemical cross-linking with mass sites of CL identified close to the proton transfer pathway in CIII spectrometry to identify protein interactors of SS-31 in mitochon- and CIV suggest a role of CL in proton uptake through the IMM dria.
    [Show full text]
  • Respiration with Pyruvate, Glutamate and Malate
    O2k-Protocols Mitochondrial Physiology Network 11.04: 1-9 (2011) 2007-2011 OROBOROS Version 6: 2011-12-11 Mitochondrial Pathways to Complex I: Respiration with Pyruvate, Glutamate and Malate Erich Gnaiger Medical University of Innsbruck D. Swarovski Research Laboratory A-6020 Innsbruck, Austria OROBOROS INSTRUMENTS Corp, high-resolution respirometry Schöpfstr 18, A-6020 Innsbruck, Austria [email protected]; www.oroboros.at Section 1. Malate ......................................................... 2 Page 2. Pyruvate+Malate: PM ..................................... 3 3. Glutamate ...................................................... 4 4. Glutamate+Malate: GM .................................. 5 5. Boundary conditions ..................................... 8 6. Notes - Pitfalls .............................................. 9 Introduction Mitochondrial respiration depends on a continuous flow of substrates across the mitochondrial membranes into the matrix space. Glutamate and malate are anions which cannot permeate through the lipid bilayer of membranes and hence require carriers, which is also true for pyruvate. Various anion carriers in the inner mitochondrial membrane are involved in the transport of mitochondrial metabolites. Their distribution across the mitochondrial membrane varies mainly with ΔpH and not Δψ, since most carriers (but not the glutamate-aspartate carrier) operate non- electrogenic by anion exchange or co-transport of protons. Depending on the concentration gradients, these carriers also allow for the transport of mitochondrial metabolites from the mitochondria into the cytosol, or for the loss of intermediary metabolites into the incubation medium. Export of intermediates of the tricarboxylic acid (TCA) cycle plays an important metabolic role in the intact cell. This must be considered when interpreting [email protected] www.oroboros.at MiPNet11.04 MitoPathways to CI 2 the effect on respiration of specific substrates used in studies of mitochondrial preparations (Gnaiger 2009).
    [Show full text]